• A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma

  NCT02082977

  TerminatedInterventionalPhase 1Updated Feb 25, 2020
• A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.

  NCT04923048

  Unknown statusInterventionalPhase 1Phase 2Updated May 22, 2023
• A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

  NCT05828589

  TerminatedInterventionalPhase 1Updated Jul 14, 2026
• A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

  NCT01943851

  CompletedInterventionalPhase 2Updated Oct 1, 2024
• A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma

  NCT06561425

  TerminatedInterventionalPhase 1Phase 2Updated Jun 30, 2026
• A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

  NCT06090539

  RecruitingInterventionalPhase 1Phase 2Updated Aug 18, 2026

ClinicalTrials.gov ID

NCT07607925

Lead Sponsor

GlaxoSmithKlineINDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 1Phase 2

Enrollment

49Estimated

Last Update Posted

Jun 18, 2026Actual

Start Date

Jun 12, 2026Estimated

Primary Completion Date

Sep 24, 2029Estimated

Completion Date

Sep 24, 2029Estimated

Official Title

A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Brief Summary

The goal of this clinical trial is to learn if drug GSK5926371 works to treat a form of B-cell cancer (a type of blood cancer) that has returned or failed to respond to prior therapies in adults. The study will primarily assess the drugs safety and tolerability in participants. Additionally, it seeks to determine the clinical efficacy and pharmacokinetic (PK) properties of GSK5926371.

• Lymphoma, Non-Hodgkin

• GSK5926371

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Has histologically confirmed Relapsed/Refractory (R/R) B-NHL, for which systemic treatment is indicated,

  1. Has measurable disease,
  2. Has received at least 2 prior lines of systemic anti-neoplastic therapy, including an anti-CD20-containing combination appropriate for the indication;
  3. Has documented disease relapse, progression or disease refractory to the most recent line of therapy, per Lugano criteria.:

• Willing to use adequate contraception (Participant of childbearing potential [POCBP] only).

• Is capable of giving signed informed consent

• Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

• Has adequate organ function.

Exclusion Criteria:

• Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas (e.g., breast, cervix, bladder) that have been resected with no evidence of metastatic disease.
• Has had any major surgery within 4 weeks prior to the first dose of GSK5926371 or has not recovered from prior surgeries or complications.
• Has a history of Progressive multifocal leukoencephalopathy (PML), current central nervous system (CNS) involvement by lymphoma, or a history of significant CNS disease such as uncontrolled seizures, stroke, epilepsy, CNS vasculitis, and neurodegenerative conditions.
• Has an active uncontrolled infection.
• Has received a prior Allogeneic stem cell transplant (allo-SCT) within 12 months prior to the first dose of GSK5926371 or has active graft-versus-host disease requiring systemic immunosuppressive therapy.
• Has received a prior autologous stem cell transplant within 100 days prior to the first dose of GSK5926371.
• Has received prior treatment with Chimeric antigen receptor T-cell (CAR-T) therapy within 12 weeks of first GSK5926371 administration.
• Has received prior treatment with CD19- or CD20-targeting Bispecific antibody (BsAbs) within 8 weeks of the first dose of study intervention.
• Has QT interval corrected (QTc) >450 milliseconds (msec) or QTc >480 msec for participants with bundle branch block.
• Has significant cardiovascular disease such as uncontrolled arrhythmias, Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification, ejection fraction <=45% by any methods in the 12 months of enrollment, unstable angina or acute coronary syndrome including myocardial infarction within 6 months of enrollment.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Sequential Assignment

Masking

None (Open Label)

Lead Sponsor

GlaxoSmithKlineINDUSTRY

GSKClinicalSupportHD@gsk.com877-379-3718

GSKClinicalSupportHD@gsk.com877-379-3718